ANAPTYSBIO INC (ANAB)
US0327241065 - Common Stock
Actym Therapeutics Appoints Thomas Smart as CEO
/PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive...
AnaptysBio Breaks Below 200-Day Moving Average - Notable for ANAB
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
A powerfully bullish new analyst take on the company helped it rally on the market.
Commit To Buy AnaptysBio At $12.50, Earn 8.4% Annualized Using Options
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end...
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
Stifel starts AnaptysBio at buy, cites upcoming catalysts (NASDAQ:ANAB)
Stifel has initiated coverage of AnaptysBio (ANAB) with a buy rating, stating it views the company as a “key player in the next wave of immune cell modulatory t
AnaptysBio stock gains on bullish view from Piper Sandler
AnaptysBio (ANAB) stock rises after Piper Sandler initiated coverage with a bullish view, citing a catalyst-rich period for the biotech in 2024/25. Read more here.
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
ANAB Crosses Above Key Moving Average Level
Commit To Purchase AnaptysBio At $12.50, Earn 15.4% Annualized Using Options
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolioIND filing to support...
Oversold Conditions For AnaptysBio (ANAB)
Anaptys Named a BioSpace 2024 Best Places to Work Winner
Anaptys Named a BioSpace 2024 Best Places to Work Winner
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
Initiated a global Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist Initiating in Q4 2023 a global Phase 2 trial to...
Anaptys Announces Participation in November Investor Conferences
Anaptys Announces Participation in November Investor Conferences
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage...
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to...
Relative Strength Alert For AnaptysBio
AnaptysBio announces appointment of John Orwin as chairman of the board (NASDAQ:ANAB)
Clinical-stage biotechnology company AnaptysBio (ANAB) Monday announced the appointment of John Orwin as chairman of AnaptysBio's board of directors.After more than 15 years serving...
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
After more than 15 years serving on AnaptysBio’s Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board...